Plasma ceramides are associated with MRI-based liver fat content but not with noninvasive scores of liver fibrosis in patients with type 2 diabetes
Authors' conclusion
Plasma ceramide levels are associated with liver steatosis in patients with type 2 diabetes, independently of traditional risk factors for NAFLD. The independent association between plasma ceramides and liver steatosis adds new insights regarding the relationship between ceramides and NAFLD in type 2 diabetes.
Study context
- Population
- Patients with T2D
- Participants
- 255 vs 80
- Exposure
- GEPSAD vs LIRA-NAFLD
- GEPSADn = 255
- LIRA-NAFLDn = 80
- Outcome
- Association of circulating ceramides with liver steatosis assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF)
Methodological detailssingle-centre, validation cohort
- Single-centre
- Validation cohort
Main finding
As reported in the abstract
MRI-PDFF liver fat content vs plasma ceramides (GEPSAD)
- Univariate association with total ceramides
- r = 0.232, p = 0.0002
- Univariate association with 18:0, 20:0, 22:0 and 24:0 ceramides
- p ≤ 0.0003 for all
- Multivariate (adjusted for age, diabetes duration, BMI, dyslipidemia): total ceramides
- p = 0.001
- Multivariate: 18:0 ceramide
- p = 0.006
- Multivariate: 22:0 ceramide
- p = 0.0009
- Multivariate: 24:0 ceramide
- p = 0.0001
Observational data: associations, not effects.
Secondary outcomes
Liver steatosis (liver fat content > 5.56%)
Noninvasive fibrosis scores vs plasma ceramides
- No significant association after adjustment for age in both cohorts
Original publication
Plasma ceramides are associated with MRI-based liver fat content but not with noninvasive scores of liver fibrosis in patients with type 2 diabetes. Cardiovasc Diabetol. Published 8 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →